The contributions of cooperative groups to performing large-cohort clinical trials and long-term survivorship studies have facilitated advances in treatment, supportive care and, ultimately, survival for patients with paediatric cancers. As a result, the number of childhood cancer survivors in the USA alone is expected to reach almost 580,000 by 2040.
Despite these substantial improvements, childhood cancer survivors continue to have an elevated burden of chronic disease and an excess risk of early death compared with the general population and therefore constitute a large, medically vulnerable population for which delivery of high-quality, personalized care is much needed.
Data from large survivorship cohorts have enabled the identification of compelling associations between paediatric cancers, cancer therapy and long-term health conditions. Effectively translating these findings into clinical care that improves the quality and quantity of life for survivors remains an important focus of ongoing research. Continued development of well-designed clinical studies incorporating dissemination and implementation strategies with input from patient advocates and other key stakeholders is crucial to overcoming these gaps.
This Review highlights the global progress made and future efforts that will be needed to further increase the quality and quantity of life-years gained for childhood cancer survivors.
Αυτό το άρθρο παρέχει αποκλειστικά ενημερωτική υποστήριξη και δεν υποκαθιστά την επαγγελματική ιατρική συμβουλή, διάγνωση ή θεραπεία. Συμβουλεύεστε πάντα τον επαγγελματία υγείας σας για ιατρικές αποφάσεις.
Το περιεχόμενο αυτό δημιουργήθηκε στο πλαίσιο του έργου EU-CAYAS-NET, το οποίο συγχρηματοδοτήθηκε από το πρόγραμμα EU4Health την περίοδο 2022-2025 (συμφωνία επιχορήγησης αριθ. 101056918).
